Skip to main content

SRRK Scholar Rock Holding Corporation

Healthcare

43.25 +0.76 +1.79% Close 10/28
Since 2024-11-26 +14.7%
Open
43.82
High
43.93
Low
42.48
Prev close
42.49
Volume
1.7M
Amplitude
3.41%
P/B
20.4
Revenue YoY (TTM)
-100.0%
52W 27.07 61.76

Is Scholar Rock Holding Corporation a buy? Fundamentals and valuation first

As of 2026-10-27

Momentum: Good, Risk / liquidity: Good; Valuation: Expensive, Quality: Weak, Growth: Weak.

Valuation Expensive Free-cash-flow yield is Average; Price / book is Expensive.
TTM P/E -12.84 N/A
Price / book 20.39 96th percentile Expensive
Free-cash-flow yield (%) -5.73 32th percentile Average
Quality Weak ROE, TTM is Lagging.
ROE, TTM (%) -161 7th percentile Lagging
Operating margin, TTM (%) — N/A
FCF margin, TTM (%) — N/A
Growth Weak Diluted EPS growth, TTM YoY is Good, but Revenue growth, TTM YoY is Lagging.
Revenue growth, TTM YoY (%) -100 3th percentile Lagging
Diluted EPS growth, TTM YoY (%) 11.07 62th percentile Good
Momentum Good 240-day return is Top, but 60-day return is Average.
60-day return (%) -7.33 46th percentile Average
240-day return (%) 38 83th percentile Top
Risk / liquidity Good 20-day dollar volume is Top, but 60-day annualized volatility is Average.
20-day dollar volume 77,515,786 85th percentile Top
60-day annualized volatility (%) 48.64 54th percentile Average
FinLab Studio

From Scholar Rock Holding Corporation to every stock like it

AI finds several complementary traits of Scholar Rock Holding Corporation across different dimensions, combines them into a multifactor strategy, and backtests it against the market.

Screen stocks like Scholar Rock Holding Corporation

Scholar Rock Holding Corporation (SRRK) peers and tracking

Watchlist

This page refreshes daily after the close. Add Scholar Rock Holding Corporation to your watchlist to track signal changes on your next visit.

Scholar Rock Holding Corporation (SRRK) quant signal backtests

Market-wide momentum baseline

Across 99,332 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.50%, a 58.5% positive-return rate, and +3.14 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

More history: Signals not active now

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

14 times historically; 60-day forward avg -0.75%, win rate 46.2%, beating the market by -5.13 pts on average.

Top-quintile 6-month momentum

Pending

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

15 times historically; 60-day forward avg +18.48%, win rate 71.4%, beating the market by +12.74 pts on average.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

10 times historically; 60-day forward avg +2.86%, win rate 40%, beating the market by -2.06 pts on average.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.